BriaCell Therapeutics Corp. continues to enroll patients in its Phase 1/2a clinical trial of BriaVax for the treatment of advanced breast cancer.

BMT is one of the fastest growing hospital procedures according to AHRQ; US Dept. of HHS. Iomab-B offers a better solution - cheaper, faster, safer, and more effective - than the current standard of care.

edgePath Pharmaceuticals, Inc. (HPPI) announced the company has been granted a Type C meeting with the U.S. FDA to discuss the interim results from the company's Phase 2b clinical study of SUBA-Cap.

This morning, MabVax Therapeutics closed a public offering of $4.1 million in cash. The company offered 1.343 million shares.

Matinas BioPharma Holdings, Inc. reported financial results for the first quarter ending March 31, 2017. The company also provided an update on anti-infective drug candidates, MAT2203 and MAT2501.

Oryzon is focused on developing epigenetic-based therapies and personalized drugs from its proprietary platform technology. Over the past several months, management has made significant progress moving the pipeline forward.

BriaCell Therapeutics remains one of my favorite under-the-radar immuno-oncology names. Finally, the CEO just invested $1.5 million of his own money into the story and that alone should warrant investor's attention.

The market is asleep on BioSig right now. Perhaps they see an upstart player not capable of competing with behemoths like GE and J&J.

BrainStorm is expanding its management team and focusing on securing non-dilutive capital. The company has the cash to begin the study and an excellent track record of bringing in non-dilutive grants to keep shareholder dilution to a minimum.

Axsome has good insider ownership, plenty of cash, drugs with proven mechanisms of action, strong IP, and plenty of catalysts. Should it be in your portfolio?

RedHill Biopharma Ltd held an R&D Day highlighting for investors the clinical and commercial attributes of BEKINDA (RHB-102).

The letter highlights some of the recent positive developments for the company, including the collaboration with Mayo Clinic and the recent $5.0 million financing.

BrainStorm’s next step in the development of NurOwn is to initiate a Phase 3 clinical study in the U.S. This will be a major milestone for the company and establish an important Catalyst for the shares once initiated.

MSKCC continues to be an excellent clinical investigator for MabVax Therapeutics. Cash is perhaps the only missing piece to the story, which I expect management to address in the near future.

I think VistaGen's stock has tremendous upside potential that today's price. The company is likely to raise cash at some point over the next several months.

I ultimately believe that RedHill will look to partner Yeliva for Phase 3 development, and RedHill is certainly well-funded today with $66 million on hand as of December 2016, but every bit of financial assistance helps.